KYMR vs. CRVS
KYMR (Kymera Therapeutics, Inc.) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, KYMR returned 18.22%/yr vs 44.07%/yr for CRVS. At a 0.30 correlation, their price movements are largely independent.
Performance
KYMR vs. CRVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KYMR achieves a 41.88% return, which is significantly lower than CRVS's 91.04% return.
KYMR
- 1D
- -7.50%
- 1M
- 28.07%
- 6M
- 51.05%
- YTD
- 41.88%
- 1Y
- 148.20%
- 3Y*
- 70.84%
- 5Y*
- 18.22%
- 10Y*
- —
CRVS
- 1D
- -6.13%
- 1M
- 23.30%
- 6M
- 117.93%
- YTD
- 91.04%
- 1Y
- 255.31%
- 3Y*
- 81.51%
- 5Y*
- 44.07%
- 10Y*
- 0.47%
KYMR vs. CRVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
KYMR Kymera Therapeutics, Inc. | 41.88% | 93.41% | 58.01% | 2.00% | -60.69% | 2.40% | 77.14% |
CRVS Corvus Pharmaceuticals, Inc. | 91.04% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -11.00% |
Correlation
The correlation between KYMR and CRVS is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.39 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.35 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Aug 21, 2020 | 0.30 |
Fundamentals
KYMR:
$9.08B
CRVS:
$1.24B
KYMR:
-$3.51
CRVS:
-$0.52
KYMR:
6.99
CRVS:
5.50
KYMR:
$51.47M
CRVS:
$0.00
KYMR:
$17.10M
CRVS:
-$26.00K
KYMR:
-$323.05M
CRVS:
-$47.43M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KYMR vs. CRVS — Risk / Return Rank
KYMR
CRVS
KYMR vs. CRVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KYMR | CRVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.89 | ||
| Sortino ratioReturn per unit of downside risk | -1.35 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.56 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 5.37 | 4.56 | +0.82 |
| Martin ratioReturn relative to average drawdown | 12.76 | 8.93 | +3.83 |
Loading charts...
Drawdowns
KYMR vs. CRVS - Drawdown Comparison
The maximum KYMR drawdown since its inception was -87.51%, smaller than the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for KYMR and CRVS.
Loading charts...
Drawdown Indicators
| KYMR | CRVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.51% | -96.97% | +9.46% |
Max Drawdown (1Y)Largest decline over 1 year | -27.74% | -56.43% | +28.69% |
Max Drawdown (3Y)Largest decline over 3 years | -59.83% | -70.50% | +10.67% |
Max Drawdown (5Y)Largest decline over 5 years | -83.54% | -92.40% | +8.86% |
Max Drawdown (10Y)Largest decline over 10 years | — | -96.97% | — |
Current DrawdownCurrent decline from peak | -7.50% | -42.36% | +34.86% |
Average DrawdownAverage peak-to-trough decline | -48.81% | -69.10% | +20.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.66% | 28.72% | -17.06% |
Volatility
KYMR vs. CRVS - Volatility Comparison
Kymera Therapeutics, Inc. (KYMR) has a higher volatility of 23.57% compared to Corvus Pharmaceuticals, Inc. (CRVS) at 13.75%. This indicates that KYMR's price experiences larger fluctuations and is considered to be riskier than CRVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KYMR | CRVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.57% | 13.75% | +9.82% |
Volatility (6M)Calculated over the trailing 6-month period | 36.25% | 111.46% | -75.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 64.26% | 179.86% | -115.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.95% | 131.15% | -58.20% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 75.47% | 111.20% | -35.73% |
Dividends
KYMR vs. CRVS - Dividend Comparison
Neither KYMR nor CRVS has paid dividends to shareholders.
Financials
KYMR vs. CRVS - Financials Comparison
This section allows you to compare key financial metrics between Kymera Therapeutics, Inc. and Corvus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
KYMR and CRVS have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KYMR has higher volatility (23.57%) compared to CRVS (13.75%). In terms of maximum drawdown, KYMR dropped -87.51% vs CRVS's -96.97%.
KYMR currently has the higher Sharpe Ratio (2.32 vs 1.43), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KYMR and CRVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer